Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Peer-review started: July 28, 2021
First decision: August 19, 2021
Revised: August 24, 2021
Accepted: October 14, 2021
Article in press: October 14, 2021
Published online: December 6, 2021
Vancomycin and teicoplanin are important drugs in the clinical treatment of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis lung infections.
Single-drug treatment of lung infections is not effective.
We want to compare the therapeutic effects of conventional antibacterial therapy (vancomycin only) and vancomycin plus teicoplanin.
We selected 86 patients with methicillin-resistant Staphylococcus aureus (MRSA) or Staphylococcus epidermidis lung infections and divided them into a study group and a control group, with 43 cases in each group.
The study group was more effective than the control group.
The combined teicoplanin/vancomycin treatment of patients with pulmonary methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis infections resulted in improved clinical responses.
The combined application of antibacterial drugs increases the cure rate of the disease.